Skip to main content

Advertisement

SpringerLink
Log in

Parkin in Parkinson’s Disease and Cancer: a Double-Edged Sword

  • Published:
Molecular Neurobiology Aims and scope Submit manuscript

Abstract

Parkin for more than a decade has been portrayed as a neuroprotector gene is now increasingly emerging as a multifaceted gene that can exert entirely opposite effects i.e., both cell proliferation and apoptosis. Parkinson’s disease, a neurological disease, progresses due to excess in cell death, while, in case of cancer, cell death normally fails to occur. Parkin, an E3 ubiquitin ligase, was first identified as a gene implicated in autosomal recessive juvenile Parkinsonism, but several evidences indicate that Parkin is a tumor suppressor gene, involved in a variety of cancers. It is hard to imagine that two entirely different classes of disease, like cancer and Parkinson’s disease, can converge at a critical point attributable to a single gene, Parkin. This mysterious and hidden connection may prove a boon in disguise and has raised hopes that studying the biology of one disease may help to identify novel targets of therapy for the other. In this Parkinson’s disease–cancer story, if the detail of Parkin pathway is unraveled and gaps in the storyline are properly filled up, we may end getting an entirely new therapeutic option. This review mainly highlights the recent literature which suggests how Parkin gene regulates the various hallmarks of both the Parkinson’s disease and cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ko HS, von Coelln R, Sriram SR, Kim SW, Chung KKK, Pletnikova O et al (2005) Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J Neurosci 25(35):7968–7978. https://doi.org/10.1523/JNEUROSCI.2172-05.2005

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  2. Shimura H, Hattori N, Kubo S i, Mizuno Y, Asakawa S, Minoshima S et al (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25(3):302–305. https://doi.org/10.1038/77060

    Article  PubMed  CAS  Google Scholar 

  3. Debatisse M, Le Tallec B, Letessier A, Dutrillaux B, Brison O (2012) Common fragile sites: mechanisms of instability revisited. Trends Genet 28(1):22–32. https://doi.org/10.1016/j.tig.2011.10.003

    Article  PubMed  CAS  Google Scholar 

  4. West AB, Kapatos G, O’Farrell C, Gonzalez-de-Chavez F, Chiu K, Farrer MJ et al (2004) N-myc regulates parkin expression. J Biol Chem 279(28):28896–28902. https://doi.org/10.1074/jbc.M400126200

    Article  PubMed  CAS  Google Scholar 

  5. Zhang C, Lin M, Wu R, Wang X, Yang B, Levine AJ, Hu W, Feng Z (2011) Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect. Proc Natl Acad Sci U S A 108(39):16259–16264. https://doi.org/10.1073/pnas.1113884108

    Article  PubMed  PubMed Central  Google Scholar 

  6. Bouman L, Schlierf A, Lutz AK, Shan J, Deinlein A, Kast J, Galehdar Z, Palmisano V et al (2011) Parkin is transcriptionally regulated by ATF4: evidence for an interconnection between mitochondrial stress and ER stress. Cell Death Differ 18(5):769–782. https://doi.org/10.1038/cdd.2010.142

    Article  PubMed  CAS  Google Scholar 

  7. Klinkenberg M, Gispert S, Dominguez-Bautista JA, Braun I, Auburger G, Jendrach M (2012) Restriction of trophic factors and nutrients induces PARKIN expression. Neurogenetics 13(1):9–21. https://doi.org/10.1007/s10048-011-0303-8

    Article  PubMed  CAS  Google Scholar 

  8. Wang H-Q, Imai Y, Kataoka A, Takahashi R (2007) Cell type-specific upregulation of Parkin in response to ER stress. Antioxid Redox Signal 9(5):533–542. https://doi.org/10.1089/ars.2006.1522

    Article  PubMed  CAS  Google Scholar 

  9. Kim K-Y, Stevens MV, Akter MH, Rusk SE, Huang RJ, Cohen A, Noguchi A, Springer D et al (2011) Parkin is a lipid-responsive regulator of fat uptake in mice and mutant human cells. J Clin Invest 121(9):3701–3712. https://doi.org/10.1172/JCI44736

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Ikeuchi K, Marusawa H, Fujiwara M, Matsumoto Y, Endo Y, Watanabe T, Iwai A, Sakai Y et al (2009) Attenuation of proteolysis-mediated cyclin E regulation by alternatively spliced Parkin in human colorectal cancers. Int J Cancer 125(9):2029–2035. https://doi.org/10.1002/ijc.24565

    Article  PubMed  CAS  Google Scholar 

  11. Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, Ling SC, Sun E et al (2011) Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci 14(4):459–468. https://doi.org/10.1038/nn.2779

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Trempe J-F, Sauvé V, Grenier K, Seirafi M, Tang MY, Ménade M et al (2013) Structure of parkin reveals mechanisms for ubiquitin ligase activation. Science 340(6139):1451–1455. https://doi.org/10.1126/science.1237908

    Article  PubMed  CAS  Google Scholar 

  13. Chaugule VK, Burchell L, Barber KR, Sidhu A, Leslie SJ, Shaw GS, Walden H (2011) Autoregulation of Parkin activity through its ubiquitin-like domain. EMBO J 30(14):2853–2867. https://doi.org/10.1038/emboj.2011.204

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Lazarou M, Narendra DP, Jin SM, Tekle E, Banerjee S, Youle RJ (2013) PINK1 drives Parkin self-association and HECT-like E3 activity upstream of mitochondrial binding. J Cell Biol 200(2):163–172. https://doi.org/10.1083/jcb.201210111

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Ko HS, Lee Y, Shin J-H, Karuppagounder SS, Gadad BS, Koleske AJ, Pletnikova O, Troncoso JC et al (2010) Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin’s ubiquitination and protective function. Proc Natl Acad Sci U S A 107(38):16691–16696. https://doi.org/10.1073/pnas.1006083107

    Article  PubMed  PubMed Central  Google Scholar 

  16. Avraham E, Rott R, Liani E, Szargel R, Engelender S (2007) Phosphorylation of Parkin by the cyclin-dependent kinase 5 at the linker region modulates its ubiquitin-ligase activity and aggregation. J Biol Chem 282(17):12842–12850. https://doi.org/10.1074/jbc.M608243200

    Article  PubMed  CAS  Google Scholar 

  17. Yamamoto A, Friedlein A, Imai Y, Takahashi R, Kahle PJ, Haass C (2005) Parkin phosphorylation and modulation of its E3 ubiquitin ligase activity. J Biol Chem 280(5):3390–3399. https://doi.org/10.1074/jbc.M407724200

    Article  PubMed  CAS  Google Scholar 

  18. Rubio de la Torre E, Luzón-Toro B, Forte-Lago I, Minguez-Castellanos A, Ferrer I, Hilfiker S (2009) Combined kinase inhibition modulates parkin inactivation. Hum Mol Genet 18:809–823. https://doi.org/10.1093/hmg/ddn407

    Article  PubMed  CAS  Google Scholar 

  19. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S et al (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392(6676):605–608. https://doi.org/10.1038/33416

    Article  PubMed  CAS  Google Scholar 

  20. Cesari R, Martin ES, Calin GA, Pentimalli F, Bichi R, McAdams H et al (2003) Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci U S A 100(10):5956–5961. https://doi.org/10.1073/pnas.0931262100

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  21. Denison SR, Callahan G, Becker NA, Phillips LA, Smith DI (2003) Characterization of FRA6E and its potential role in autosomal recessive juvenile parkinsonism and ovarian cancer. Genes Chromosom Cancer 38(1):40–52. https://doi.org/10.1002/gcc.10236

    Article  PubMed  CAS  Google Scholar 

  22. Mehdi SJ, Alam MS, Batra S, Rizvi MMA (2011) Allelic loss of 6q25-27, the PARKIN tumor suppressor gene locus, in cervical carcinoma. Med Oncol 28(4):1520–1526. https://doi.org/10.1007/s12032-010-9633-x

    Article  PubMed  CAS  Google Scholar 

  23. Yang YX, Wood NW, Latchman DS (2009) Molecular basis of Parkinsonʼs disease. Neuroreport 20(2):150–156. https://doi.org/10.1097/WNR.0b013e32831c50df

    Article  PubMed  CAS  Google Scholar 

  24. Antony PMA, Diederich NJ, Krüger R, Balling R (2013) The hallmarks of Parkinson’s disease. FEBS J 280(23):5981–5993. https://doi.org/10.1111/febs.12335

    Article  PubMed  CAS  Google Scholar 

  25. Lücking CB, Dürr A, Bonifati V, Vaughan J, De Michele G, Gasser T, Harhangi BS, Meco G et al (2000) Association between early-onset Parkinson’s disease and mutations in the Parkin gene. N Engl J Med 342(21):1560–1567. https://doi.org/10.1056/NEJM200005253422103

    Article  PubMed  Google Scholar 

  26. Abbas N, Lucking CB, Ricard S, Durr A, Bonifati V, De Michele G, Bouley S, Vaughan JR et al (1999) A wide variety of mutations in the Parkin gene are responsible for autosomal recessive parkinsonism in Europe. Hum Mol Genet 8(4):567–574. https://doi.org/10.1093/hmg/8.4.567

    Article  PubMed  CAS  Google Scholar 

  27. Hart MP, Xu A (2009) Mice expressing mutant Parkin exhibit hallmark features of Parkinson’s disease. J Neurosci 29(23):7392–7394. https://doi.org/10.1523/JNEUROSCI.1719-09.2009

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  28. Higashi Y, Asanuma M, Miyazaki I, Hattori N, Mizuno Y, Ogawa N (2004) Parkin attenuates manganese-induced dopaminergic cell death. J Neurochem 89(6):1490–1497. https://doi.org/10.1111/j.1471-4159.2004.02445.x

    Article  PubMed  CAS  Google Scholar 

  29. Petrucelli L, O’Farrell C, Lockhart PJ, Baptista M, Kehoe K, Vink L et al (2002) Parkin protects against the toxicity associated with mutant α-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 36(6):1007–1019. https://doi.org/10.1016/S0896-6273(02)01125-X

    Article  PubMed  CAS  Google Scholar 

  30. TAKAHASHI R, IMAI Y, HATTORI N, MIZUNO Y (2006) Parkin and endoplasmic reticulum stress. Ann N Y Acad Sci 991(1):101–106. https://doi.org/10.1111/j.1749-6632.2003.tb07467.x

    Article  Google Scholar 

  31. Tsai YC, Fishman PS, Thakor NV, Oyler GA (2003) Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. J Biol Chem 278(24):22044–22055. https://doi.org/10.1074/jbc.M212235200

    Article  PubMed  CAS  Google Scholar 

  32. Staropoli JF, McDermott C, Martinat C, Schulman B, Demireva E, Abeliovich A (2003) Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron 37(5):735–749. https://doi.org/10.1016/S0896-6273(03)00084-9

    Article  PubMed  CAS  Google Scholar 

  33. Chung KKK, Thomas B, Li X, Pletnikova O, Troncoso JC, Marsh L et al (2004) S-nitrosylation of parkin regulates ubiquitination and compromises parkin’s protective function. Science 304(5675):1328–1331. https://doi.org/10.1126/science.1093891

    Article  PubMed  CAS  Google Scholar 

  34. Newmeyer DD, Ferguson-Miller S (2003) Mitochondria: releasing power for life and unleashing the machineries of death. Cell 112(4):481–490. https://doi.org/10.1016/S0092-8674(03)00116-8

    Article  PubMed  CAS  Google Scholar 

  35. Kuroda Y, Mitsui T, Kunishige M, Shono M, Akaike M, Azuma H, Matsumoto T (2006) Parkin enhances mitochondrial biogenesis in proliferating cells. Hum Mol Genet 15(6):883–895. https://doi.org/10.1093/hmg/ddl006

    Article  PubMed  CAS  Google Scholar 

  36. Rothfuss O, Fischer H, Hasegawa T, Maisel M, Leitner P, Miesel F, Sharma M, Bornemann A et al (2009) Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair. Hum Mol Genet 18(20):3832–3850. https://doi.org/10.1093/hmg/ddp327

    Article  PubMed  CAS  Google Scholar 

  37. Palacino JJ, Sagi D, Goldberg MS, Krauss S, Motz C, Wacker M, Klose J, Shen J (2004) Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 279(18):18614–18622. https://doi.org/10.1074/jbc.M401135200

    Article  PubMed  CAS  Google Scholar 

  38. Surmeier DJ (2007) Calcium, ageing, and neuronal vulnerability in Parkinson’s disease. Lancet Neurol 6(10):933–938. https://doi.org/10.1016/S1474-4422(07)70246-6

    Article  PubMed  CAS  Google Scholar 

  39. Sandebring A, Dehvari N, Perez-Manso M, Thomas KJ, Karpilovski E, Cookson MR, Cowburn RF, Cedazo-Mínguez A (2009) Parkin deficiency disrupts calcium homeostasis by modulating phospholipase C signalling. FEBS J 276(18):5041–5052. https://doi.org/10.1111/j.1742-4658.2009.07201.x

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  40. Goldberg MS, Fleming SM, Palacino JJ, Cepeda C, Lam HA, Bhatnagar A, Meloni EG, Wu N et al (2003) Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 278(44):43628–43635. https://doi.org/10.1074/jbc.M308947200

    Article  PubMed  CAS  Google Scholar 

  41. Kitada T, Pisani A, Karouani M, Haburcak M, Martella G, Tscherter A, Platania P, Wu B et al (2009) Impaired dopamine release and synaptic plasticity in the striatum of Parkin−/− mice. J Neurochem 110(2):613–621. https://doi.org/10.1111/j.1471-4159.2009.06152.x

    Article  PubMed  CAS  Google Scholar 

  42. Lim K-L, Dawson VL, Dawson TM (2006) Parkin-mediated lysine 63-linked polyubiquitination: a link to protein inclusions formation in Parkinson’s and other conformational diseases? Neurobiol Aging 27(4):524–529. https://doi.org/10.1016/j.neurobiolaging.2005.07.023

    Article  PubMed  CAS  Google Scholar 

  43. Sarraf SA, Raman M, Guarani-Pereira V, Sowa ME, Huttlin EL, Gygi SP, Harper JW (2013) Landscape of the PARKIN-dependent ubiquitylome in response to mitochondrial depolarization. Nature 496(7445):372–376. https://doi.org/10.1038/nature12043

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  44. Ziviani E, Tao RN, Whitworth AJ (2010) Drosophila parkin requires PINK1 for mitochondrial translocation and ubiquitinates mitofusin. Proc Natl Acad Sci U S A 107(11):5018–5023. https://doi.org/10.1073/pnas.0913485107

    Article  PubMed  PubMed Central  Google Scholar 

  45. Kahle PJ, Haass C (2004) How does parkin ligate ubiquitin to Parkinson’s disease? EMBO Rep 5(7):681–685. https://doi.org/10.1038/sj.embor.7400188

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  46. Li H, Guo M, Dodson MW, Guo M, Mukhopadhyay D, Riezman H et al (2009) Protein degradation in Parkinson disease revisited: it’s complex. J Clin Invest 119(3):442–444. https://doi.org/10.1172/JCI38619

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  47. Dehay B, Martinez-Vicente M, Caldwell GA, Caldwell KA, Yue Z, Cookson MR, Klein C, Vila M et al (2013) Lysosomal impairment in Parkinson’s disease. Mov Disord 28(6):725–732. https://doi.org/10.1002/mds.25462

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  48. Lee J-K, Tran T, Tansey MG (2009) Neuroinflammation in Parkinson’s disease. J NeuroImmune Pharmacol 4(4):419–429. https://doi.org/10.1007/s11481-009-9176-0

    Article  PubMed  PubMed Central  Google Scholar 

  49. Rodríguez-Navarro JA, Casarejos MJ, Menéndez J, Solano RM, Rodal I, Gómez A, et al. (2017)Mortality, oxidative stress and tau accumulation during ageing in parkin null mice. J Neurochem 2007;0:070710052154006–??? doi:https://doi.org/10.1111/j.1471-4159.2007.04762.x.

  50. Schmidt S, Linnartz B, Mendritzki S, Sczepan T, Lübbert M, Stichel CC et al (2011) Genetic mouse models for Parkinson’s disease display severe pathology in glial cell mitochondria. Hum Mol Genet 20(6):1197–1211. https://doi.org/10.1093/hmg/ddq564

    Article  PubMed  CAS  Google Scholar 

  51. Casarejos MJ, Solano RM, Menéndez J, Rodríguez-Navarro JA, Correa C, García de Yébenes J, Mena MA (2005) Differential effects of l-DOPA on monoamine metabolism, cell survival and glutathione production in midbrain neuronal-enriched cultures from parkin knockout and wild-type mice. J Neurochem 94(4):1005–1014. https://doi.org/10.1111/j.1471-4159.2005.03249.x

    Article  PubMed  CAS  Google Scholar 

  52. Solano RM, Casarejos MJ, Menéndez-Cuervo J, Rodriguez-Navarro JA, García de Yébenes J, Mena MA (2008) Glial dysfunction in parkin null mice: effects of aging. J Neurosci 28(3):598–611. https://doi.org/10.1523/JNEUROSCI.4609-07.2008

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  53. Imai Y, Soda M, Takahashi R (2000) Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J Biol Chem 275(46):35661–35664. https://doi.org/10.1074/jbc.C000447200

    Article  PubMed  CAS  Google Scholar 

  54. Chew KCM, Matsuda N, Saisho K, Lim GGY, Chai C, Tan H-M, Tanaka K, Lim KL (2011) Parkin mediates apparent E2-independent monoubiquitination in vitro and contains an intrinsic activity that catalyzes polyubiquitination. PLoS One 6(5):e19720. https://doi.org/10.1371/journal.pone.0019720

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  55. Veeriah S, Morris L, Solit D, Chan TA (2010) The familial Parkinson disease gene PARK2 is a multisite tumor suppressor on chromosome 6q25.2-27 that regulates cyclin E. Cell Cycle 9(8):1451–1452. https://doi.org/10.4161/cc.9.8.11583

    Article  PubMed  CAS  Google Scholar 

  56. Moore DJ, West AB, Dawson VL, Dawson TM (2005) Molecular pathophysiology of Parkinson’s disease. Annu Rev Neurosci 28(1):57–87. https://doi.org/10.1146/annurev.neuro.28.061604.135718

    Article  PubMed  CAS  Google Scholar 

  57. Yan MH, Wang X, Zhu X (2013) Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease. Free Radic Biol Med 62:90–101. https://doi.org/10.1016/j.freeradbiomed.2012.11.014

    Article  PubMed  CAS  Google Scholar 

  58. Jiang H, Ren Y, Zhao J, Feng J (2004) Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. Hum Mol Genet 13(16):1745–1754. https://doi.org/10.1093/hmg/ddh180

    Article  PubMed  CAS  Google Scholar 

  59. Aboud AA, Tidball AM, Kumar KK, Neely MD, Han B, Ess KC, Hong CC, Erikson KM et al (2015) PARK2 patient neuroprogenitors show increased mitochondrial sensitivity to copper. Neurobiol Dis 73:204–212. https://doi.org/10.1016/j.nbd.2014.10.002

    Article  PubMed  CAS  Google Scholar 

  60. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. https://doi.org/10.1016/j.cell.2011.02.013

    Article  PubMed  CAS  Google Scholar 

  61. You JS, Jones PA (2012) Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 22(1):9–20. https://doi.org/10.1016/j.ccr.2012.06.008

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  62. Vogelstein B, Kinzler KW (1993) The multistep nature of cancer. Trends Genet 9(4):138–141. https://doi.org/10.1016/0168-9525(93)90209-Z

    Article  PubMed  CAS  Google Scholar 

  63. Gupta A, Anjomani-Virmouni S, Koundouros N, Dimitriadi M, Choo-Wing R, Valle A et al (2017) PARK2 depletion connects energy and oxidative stress to PI3K/Akt activation via PTEN S-nitrosylation. Mol Cell 65:999–1013.e7. https://doi.org/10.1016/j.molcel.2017.02.019

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  64. Gong Y, Zack TI, Morris LGT, Lin K, Hukkelhoven E, Raheja R, Tan IL, Turcan S et al (2014) Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins. Nat Genet 46(6):588–594. https://doi.org/10.1038/ng.2981

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  65. Xu L, Lin D, Yin D, Koeffler HP (2014) An emerging role of PARK2 in cancer. J Mol Med (Berl) 92(1):31–42. https://doi.org/10.1007/s00109-013-1107-0

    Article  CAS  Google Scholar 

  66. Liu K, Li F, Han H, Chen Y, Mao Z, Luo J, Zhao Y, Zheng B et al (2016) Parkin regulates the activity of pyruvate kinase M2. J Biol Chem 291(19):10307–10317. https://doi.org/10.1074/jbc.M115.703066

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  67. Gong Y, Schumacher SE, Wu WH, Tang F, Beroukhim R, Chan TA (2017) Pan-cancer analysis links PARK2 to BCL-XL-dependent control of apoptosis. Neoplasia 19(2):75–83. https://doi.org/10.1016/j.neo.2016.12.006

    Article  PubMed  CAS  Google Scholar 

  68. Lee SB, Kim JJ, Nam H-J, Gao B, Yin P, Qin B, Yi SY, Ham H et al (2015) Parkin regulates mitosis and genomic stability through Cdc20/Cdh1. Mol Cell 60(1):21–34. https://doi.org/10.1016/j.molcel.2015.08.011

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  69. Yeo CWS, Ng FSL, Chai C, Tan JMM, Koh GRH, Chong YK, Koh LWH, Foong CSF et al (2012) Parkin pathway activation mitigates glioma cell proliferation and predicts patient survival. Cancer Res 72(10):2543–2553. https://doi.org/10.1158/0008-5472.CAN-11-3060

    Article  PubMed  CAS  Google Scholar 

  70. Rom O, Avezov K, Aizenbud D, Reznick AZ (2013) Cigarette smoking and inflammation revisited. Respir Physiol Neurobiol 187(1):5–10. https://doi.org/10.1016/j.resp.2013.01.013

    Article  PubMed  CAS  Google Scholar 

  71. Greene J, Whitworth A, Andrews L (2005) Genetic and genomic studies of Drosophila parkin mutants implicate oxidative stress and innate immune responses in pathogenesis. Hum Mol 14(6):799–811. https://doi.org/10.1093/hmg/ddi074

    Article  CAS  Google Scholar 

  72. Kao S-Y. Regulation of DNA repair by parkin. vol. 382. 2009. doi:https://doi.org/10.1016/j.bbrc.2009.03.048.

  73. Picchio MC, Martin ES, Cesari R, Calin GA, Yendamuri S, Kuroki T, Pentimalli F, Sarti M et al (2004) Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer. Clin Cancer Res 10(8):2720–2724. https://doi.org/10.1158/1078-0432.ccr-03-0086

    Article  PubMed  CAS  Google Scholar 

  74. Wang F, Denison S, Lai J-P, Philips LA, Montoya D, Kock N, Schüle B, Klein C et al (2004) Parkin gene alterations in hepatocellular carcinoma. Genes Chromosom Cancer 40(2):85–96. https://doi.org/10.1002/gcc.20020

    Article  PubMed  CAS  Google Scholar 

  75. Poulogiannis G, McIntyre RE, Dimitriadi M, Apps JR, Wilson CH, Ichimura K, Luo F, Cantley LC et al (2010) PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. Proc Natl Acad Sci U S A 107(34):15145–15150. https://doi.org/10.1073/pnas.1009941107

    Article  PubMed  PubMed Central  Google Scholar 

  76. Tay S-P, Yeo CWS, Chai C, Chua P-J, Tan H-M, Ang AXY, Yip DLH, Sung JX et al (2010) Parkin enhances the expression of cyclin-dependent kinase 6 and negatively regulates the proliferation of breast cancer cells. J Biol Chem 285(38):29231–29238. https://doi.org/10.1074/jbc.M110.108241

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  77. Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E, Vivanco I, Janakiraman M, Schultz N et al (2010) Somatic mutations of the Parkinson’s disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet 42(1):77–82. https://doi.org/10.1038/ng.491

    Article  PubMed  CAS  Google Scholar 

  78. Sun X, Liu M, Hao J, Li D, Luo Y, Wang X, Yang Y, Li F et al (2013) Parkin deficiency contributes to pancreatic tumorigenesis by inducing spindle multipolarity and misorientation. Cell Cycle 12(7):1133–1141. https://doi.org/10.4161/cc.24215

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  79. Yang F, Jiang Q, Zhao J, Ren Y, Sutton MD, Feng J (2005) Parkin stabilizes microtubules through strong binding mediated by three independent domains. J Biol Chem 280(17):17154–17162. https://doi.org/10.1074/jbc.M500843200

    Article  PubMed  CAS  Google Scholar 

  80. Wang H, Liu B, Zhang C, Peng G, Liu M, Li D, Gu F, Chen Q et al (2009) Parkin regulates paclitaxel sensitivity in breast cancer via a microtubule-dependent mechanism. J Pathol 218(1):76–85. https://doi.org/10.1002/path.2512

    Article  PubMed  CAS  Google Scholar 

  81. Shridhar V, Staub J, Huntley B, Cliby W, Jenkins R, Pass HI, Hartmann L, Smith d (1999) A novel region of deletion on chromosome 6q23.3 spanning less than 500 kb in high grade invasive epithelial ovarian cancer. Oncogene 18(26):3913–3918. https://doi.org/10.1038/sj.onc.1202756

    Article  PubMed  CAS  Google Scholar 

  82. Agirre X, Román-Gómez J, Vázquez I, Jiménez-Velasco A, Garate L, Montiel-Duarte C, Artieda P, Cordeu L et al (2006) Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia. Int J Cancer 118(8):1945–1953. https://doi.org/10.1002/ijc.21584

    Article  PubMed  CAS  Google Scholar 

  83. Lee K, Lee MH, Kang YW, Rhee K-J, Kim TU, Kim YS (2012) Parkin induces apoptotic cell death in TNF-α-treated cervical cancer cells. BMB Rep 45(9):526–531. https://doi.org/10.5483/BMBRep.2012.45.9.104

    Article  PubMed  CAS  Google Scholar 

  84. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C et al (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275(5308):1943–1947. https://doi.org/10.1126/science.275.5308.1943

    Article  PubMed  CAS  Google Scholar 

  85. Steeg PS (2003) Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 3(1):55–63. https://doi.org/10.1038/nrc967

    Article  PubMed  CAS  Google Scholar 

  86. Woodhouse EC, Chuaqui RF, Liotta LA (1997) General mechanisms of metastasis. Cancer 80(S8):1529–1537. https://doi.org/10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F

    Article  PubMed  CAS  Google Scholar 

  87. Korb T, Schlüter K, Enns A, Spiegel H-U, Senninger N, Nicolson GL, Haier J (2004) Integrity of actin fibers and microtubules influences metastatic tumor cell adhesion. Exp Cell Res 299(1):236–247. https://doi.org/10.1016/j.yexcr.2004.06.001

    Article  PubMed  CAS  Google Scholar 

  88. Ren Y, Jiang H, Yang F, Nakaso K, Feng J (2009) Parkin protects dopaminergic neurons against microtubule-depolymerizing toxins by attenuating microtubule-associated protein kinase activation. J Biol Chem 284(6):4009–4017. https://doi.org/10.1074/jbc.M806245200

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  89. Kaverina I, Straube A (2011) Regulation of cell migration by dynamic microtubules. Semin Cell Dev Biol 22(9):968–974. https://doi.org/10.1016/j.semcdb.2011.09.017

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  90. Koppenol WH, Bounds PL, Dang CV (2011) Otto Warburg’s contributions to current concepts of cancer metabolism. Nat Rev Cancer 11(5):325–337. https://doi.org/10.1038/nrc3038

    Article  PubMed  CAS  Google Scholar 

  91. Johnson BN, Berger AK, Cortese GP, Lavoie MJ (2012) The ubiquitin E3 ligase parkin regulates the proapoptotic function of Bax. Proc Natl Acad Sci U S A 109(16):6283–6288. https://doi.org/10.1073/pnas.1113248109

    Article  PubMed  PubMed Central  Google Scholar 

  92. Ekholm-Reed S, Goldberg MS, Schlossmacher MG, Reed SI (2013) Parkin-dependent degradation of the F-box protein Fbw7β promotes neuronal survival in response to oxidative stress by stabilizing Mcl-1. Mol Cell Biol 33(18):3627–3643. https://doi.org/10.1128/MCB.00535-13

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  93. Chen D, Gao F, Li B, Wang H, Xu Y, Zhu C, Wang G (2010) Parkin mono-ubiquitinates Bcl-2 and regulates autophagy. J Biol Chem 285(49):38214–38223. https://doi.org/10.1074/jbc.M110.101469

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  94. Kahns S, Lykkebo S, Jakobsen LD, Nielsen MS, Jensen PH (2002) Caspase-mediated parkin cleavage in apoptotic cell death. J Biol Chem 277(18):15303–15308. https://doi.org/10.1074/jbc.M111534200

    Article  PubMed  CAS  Google Scholar 

  95. Kahns S, Kalai M, Jakobsen LD, Clark BFC, Vandenabeele P, Jensen PH (2003) Caspase-1 and caspase-8 cleave and inactivate cellular parkin. J Biol Chem 278(26):23376–23380. https://doi.org/10.1074/jbc.M300495200

    Article  PubMed  CAS  Google Scholar 

  96. Palumbo E, Matricardi L, Tosoni E, Bensimon A (2010) Replication dynamics at common fragile site FRA6E. Chromosoma 119(6):575–587. https://doi.org/10.1007/s00412-010-0279-4

    Article  PubMed  CAS  Google Scholar 

  97. Lee S, She J, Deng B, Kim J, Andrade M de, Na J, et al. (2016) Multiple-level validation identifies PARK2 in the development of lung cancer and chronic obstructive pulmonary disease. Oncotarget ;5. doi:https://doi.org/10.18632/oncotarget.9954.

  98. Sherwood LM, Parris EE, Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182–1186. https://doi.org/10.1056/NEJM197111182852108

    Article  Google Scholar 

  99. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH (1994) Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269:26988–26995

    PubMed  CAS  Google Scholar 

  100. Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4(6):423–436. https://doi.org/10.1038/nrc1369

    Article  PubMed  CAS  Google Scholar 

  101. Alitalo K, Carmeliet P (2002) Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 1(3):219–227. https://doi.org/10.1016/S1535-6108(02)00051-X

    Article  PubMed  CAS  Google Scholar 

  102. Hussain SP, Harris C (2007) Inflammation and cancer: an ancient link with novel potentials. Int J Cancer.

  103. de Leseleuc L, Orlova M, Cobat A, Girard M (2013) PARK2 mediates interleukin 6 and monocyte chemoattractant protein 1 production by human macrophages. PLoS Negl Trop

  104. Manzanillo P, Ayres J, Watson R, Collins A (2013) The ubiquitin ligase parkin mediates resistance to intracellular pathogens. Nature 501(7468):512–516. https://doi.org/10.1038/nature12566

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  105. Lee MH, Cho Y, Jung BC, Kim SH, Kang YW, Pan C-H, Rhee KJ, Kim YS (2015) Parkin induces G2/M cell cycle arrest in TNF-α-treated HeLa cells. Biochem Biophys Res Commun 464(1):63–69. https://doi.org/10.1016/j.bbrc.2015.05.101

    Article  PubMed  CAS  Google Scholar 

  106. Lee S, She J, Deng B, Kim J, de Andrade M, Na J et al (2016) Multiple-level validation identifies PARK2 in the development of lung cancer and chronic obstructive pulmonary disease. Oncotarget 7(28):44211–44223. https://doi.org/10.18632/oncotarget.9954

    Article  PubMed  PubMed Central  Google Scholar 

  107. Pasparakis M, Alexopoulou L, Episkopou V, Kollias G (1996) Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 184(4):1397–1411. https://doi.org/10.1084/JEM.184.4.1397

    Article  PubMed  CAS  Google Scholar 

  108. Tripathi P, Aggarwal A. NF-kB transcription factor: a key player in the generation of immune response n.d.

  109. Bartek J, Hodny Z (2014) PARK2 orchestrates cyclins to avoid cancer. Nat Genet 46(6):527–528. https://doi.org/10.1038/ng.2992

    Article  PubMed  CAS  Google Scholar 

  110. Laird C, Jaffe E, Karpen G, Lamb M, Nelson R (1987) Fragile sites in human chromosomes as regions of late-replicating DNA. Trends Genet

  111. Durkin SG, Glover TW (2007) Chromosome fragile sites. Annu Rev Genet 41(1):169–192. https://doi.org/10.1146/annurev.genet.41.042007.165900

    Article  PubMed  CAS  Google Scholar 

  112. Moller H, Mellemkjaer L, McLaughlin JK, Olsen JH (1995) Occurrence of different cancers in patients with Parkinson’s disease. BMJ 310(6993):1500–1501. https://doi.org/10.1136/bmj.310.6993.1500

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  113. Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Møller H (2005) Atypical cancer pattern in patients with Parkinson’s disease. Br J Cancer 92(1):201–205. https://doi.org/10.1038/sj.bjc.6602279

    Article  PubMed  CAS  Google Scholar 

  114. Driver JA, Logroscino G, Buring JE, Gaziano JM, Kurth T (2007) A prospective cohort study of cancer incidence following the diagnosis of Parkinson’s disease. Cancer Epidemiol Prev Biomarkers 16(6):1260–1265. https://doi.org/10.1158/1055-9965.EPI-07-0038

    Article  Google Scholar 

  115. Becker C, Brobert GP, Johansson S, Jick SS, Meier CR (2010) Cancer risk in association with Parkinson disease: a population-based study. Parkinsonism Relat Disord 16(3):186–190. https://doi.org/10.1016/j.parkreldis.2009.11.005

    Article  PubMed  Google Scholar 

  116. Liu R, Gao X, Lu Y, Chen H (2011) Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology 76(23):2002–2009. https://doi.org/10.1212/WNL.0b013e31821e554e

    Article  PubMed  PubMed Central  Google Scholar 

  117. Pan T, Li X, Jankovic J (2011) The association between Parkinson’s disease and melanoma. Int J Cancer 128:2251–2260. https://doi.org/10.1002/ijc.25912.

    Article  PubMed  CAS  Google Scholar 

  118. Ong EL, Goldacre R, Goldacre M (2014) Differential risks of cancer types in people with Parkinson’s disease: a national record-linkage study. Eur J Cancer 50(14):2456–2462. https://doi.org/10.1016/j.ejca.2014.06.018

    Article  PubMed  Google Scholar 

  119. Minami Y, Yamamoto R, Nishikouri M, Fukao A, Hisamichi S (2000) Mortality and cancer incidence in patients with Parkinson’s disease. J Neurol 247(6):429–434. https://doi.org/10.1007/s004150070171

    Article  PubMed  CAS  Google Scholar 

Download references

Funding

This review was supported by the grant from the Department of Science and Technology (DST).

Author information

Authors and Affiliations

  1. Department of Biosciences, Jamia Millia Islamia, New Delhi, India

    Khushnuma Wahabi, Ahmad Perwez & Moshahid A Rizvi

Authors
  1. Khushnuma Wahabi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ahmad Perwez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Moshahid A Rizvi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Moshahid A Rizvi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wahabi, K., Perwez, A. & Rizvi, M.A. Parkin in Parkinson’s Disease and Cancer: a Double-Edged Sword. Mol Neurobiol 55, 6788–6800 (2018). https://doi.org/10.1007/s12035-018-0879-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12035-018-0879-1

Keywords

Search

Navigation